Biocitech appoints new ceo
Jean-Francois Boussard becomes chief executive of French life science technology park on 1 April.
Boussard joins Biocitech after a biotechnology career in academia and industry. From 1994, after six years as patents, licensing and legal director in a financial holding company, he became an independent consultant in enterprise creation and technology transfer. In 1998, he founded and was ceo of Substrat, a consultancy specialising in enterprise creation and management, project management and technology transfer in the field of biotechnology.
Prior to Substrat, Boussard was a manager for pharmaceuticals and biotechnology at France's innovation agency, Anvar, from 1982-88. From 1979-82, he was a biologist at LERS Synthelabo after an earlier spell as a research scientist at the University of Metz.
"I am looking forward to putting my scientific, legal and financial know-how to use to continue the rapid development of the park," said Boussard.
Biocitech provides offices, laboratories and technical and scientific services.
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
Roquette opens pharmaceutical innovation centre in Brazil
The Health & Pharma Solutions facility in São Paolo offers state-of-the-art laboratories for customers, with the Northeast Center for Strategic Technologies partnering with Roquette to empower young women to pursue careers in science through the Futuras Cientistas programme at the facility
Manufacturing
Samsung Bioepis and Phrontline join forces to advance best-in-class antibody-drug conjugate therapeutics for solid tumours
The pair will co-develop two investigational ADC assets directed against targets expressed in a broad range of cancers, adding a new class of bispecific and dual-payload ADC therapeutics to Samsung Bioepis' oncology portfolio